Definition
A phenothiazine with actions similar to CHLORPROMAZINE. It is used as an antipsychotic and an antiemetic.
Description
Trifluoperazine is only found in individuals that have used or taken this drug. It is a phenothiazine with actions similar to chlorpromazine. It is used as an antipsychotic and an antiemetic. [PubChem]Trifluoperazine blocks postsynaptic mesolimbic dopaminergic D1 and D2 receptors in the brain; depresses the release of hypothalamic and hypophyseal hormones and is believed to depress the reticular activating system thus affecting basal metabolism, body temperature, wakefulness, vasomotor tone, and emesis.
Top Gene Interactions
Related Pathways
General Information
- Metabolism: Hepatic. Half Life: 10-20 hours
- Uses/Sources: For the treatment of anxiety disorders, depressive symptoms secondary to anxiety and agitation.
- Symptoms: Symptoms of overdose include agitation, coma, convulsions, difficulty breathing, difficulty swallowing, dry mouth, extreme sleepiness, fever, intestinal blockage, irregular heart rate, low blood pressure, and restlessness.
- Treatment: Treatment is essentially symptomatic and supportive. Early gastric lavage is helpful. Keep patient under observation and maintain an open airway, since involvement of the extrapyramidal mechanism may produce dysphagia and respiratory difficulty in severe overdosage. Do not attempt to induce emesis because a dystonic reaction of the head or neck may develop that could result in aspiration of vomitus. Extrapyramidal symptoms may be treated with anti-parkinsonism drugs, barbiturates or Benadryl. See prescribing information for these products. Care should be taken to avoid increasing respiratory depression. If administration of a stimulant is desirable, amphetamine, dextroamphetamine or caffeine with sodium benzoate is recommended. Stimulants that may cause convulsions (e.g., picrotoxin or pentylenetetrazol) should be avoided. If hypotension occurs, the standard measures for managing circulatory shock should be initiated. If it is desirable to administer a vasoconstrictor, Levophed and Neo-Synephrine are most suitable. Other pressor agents, including epinephrine, are not recommended because phenothiazine derivatives may reverse the usual elevating action of these agents and cause a further lowering of blood pressure. (L1712)
- Route of Exposure: Oral
Mechanism of Action
Target Name | Mechanism of Action | References |
---|---|---|
Calmodulin Muscarinic acetylcholine receptor M2 Multidrug resistance protein 1 5-hydroxytryptamine receptor 2C Alpha-2A adrenergic receptor Histamine H1 receptor Sigma non-opioid intracellular receptor 1 5-hydroxytryptamine receptor 6 Troponin C, slow skeletal and cardiac muscles DNA-dependent protein kinase catalytic subunit Protein S100-A4 NADPH oxidase 1 3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase Emopamil-binding protein-like |
17145705 11716514 21129983 10592235 18459732 10991983 23199475 12477351 16033255 20421509 6149136 8522988 9525919 22835870 |
|
Potassium-transporting ATPase alpha chain 1 Alpha-1A adrenergic receptor D(2) dopamine receptor Neuron-specific vesicular protein calcyon |
Trifluoperazine blocks postsynaptic mesolimbic dopaminergic D1 and D2 receptors in the brain; depresses the release of hypothalamic and hypophyseal hormones and is believed to depress the reticular activating system thus affecting basal metabolism, body temperature, wakefulness, vasomotor tone, and emesis. |
8102973 11873706 17139284 15695070 1676523 11752352 17016423 8150214 |
Trifluoperazine Interacts with Diseases
Disease | Inference Score | References/Inference Genes |
Trigeminal Neuralgia | 17.28 |
|
Cocaine dependence | 16.48 |
|
Marijuana dependence | 13.82 |
|
Radiation Injuries, Experimental | 13.31 |
|
Brain Ischemia | 12.59 |
|
Prostatic Neoplasms | 12.53 |
|
Alzheimer's Disease | 12.39 |
|
Disease Models, Animal | 11.77 |
|
Nerve Degeneration | 11.34 |
|
Kidney Neoplasms | 10.82 |
|
Cardiomyopathies | 10.17 |
|
Myocardial Reperfusion Injury | 9.83 |
|
Lymphoma, Large B-Cell, Diffuse | 9.7 |
|
Head and Neck Neoplasms | 9.55 |
|
Neoplasm Metastasis | 9.32 |
|
Breast carcinoma | 9.25 |
|
Infertility, Female | 9.21 |
|
Ceroid lipofuscinosis, neuronal 1, infantile | 9.16 |
|
Squamous cell carcinoma | 8.99 |
|
Reperfusion Injury | 8.89 |
|